James Dentzer, Curis CEO
FDA lifts partial hold on Curis' lymphoma study — shares spike
Four months after the FDA put two clinical trials from Curis on clinical hold, the FDA is now apparently content with how the biotech will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
